The PAMAfrica consortium will conduct three clinical trials, each aiming to progress a new antimalarial therapy through the pipeline while supporting efforts to build clinical capacity and train scientists across Africa.
One trial will explore new combinations of compounds, including new chemical classes, for the treatment of uncomplicated malaria in adults and children. These compounds are all known to be fully active against all drug-resistant strains, including the artemisinin-resistant Kelch13 strains.
The second trial will test a novel formulation/ratio from Novartis of the current gold standard treatment artemether-lumefantrine in newborn infants weighing less than 5 kg or who are malnourished.
The third study will evaluate a new generation, rapid-acting treatment for severe malaria, cipargamin, also known as KAE609, which is being developed by Novartis, supported by a grant from the Wellcome Trust.